Theradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific Officer Frank brings over 20 years experience in cutting-edge orthobiologics research, with previous roles at NuVasive, SeaSpine and [….]
U.S. FDA Grants Theradaptive IDE Approval for Phase I/II Clinical Trials
Trained to Be a Leader: Luis Alvarez, CEO of Regenerative Medicine Biotech Theradaptive Since his days as a Cadet at West Point and then as a U.S. Army Officer on [….]
Theradaptive Receives MSCRF Manufacturing Assistance Grant to Help Establish New cGMP Facility in Frederick
Frederick Maryland’s Theradaptive Secures $26 Million Series A to Advance Regenerative Therapeutics
Stem Cell Research Commission Awards MSCRF $14 Million to Accelerate Cures By Alex KeownMay 24, 2023 The Maryland Stem Cell Research Commission, a division of TEDCO, handed out more than [….]
Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.
Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion. This is the third Breakthrough Designation for Theradaptive in spinal fusion, along with transforaminal interbody and posterolateral fusion, allowing it to address over 90% of lumbar spinal fusion procedures.
Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion Feb 15, 2022, 14:31 ET Theradaptive FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of [….]
Biotech companies focused on developing biodefense products and measures are well known throughout the BioHealth Capital Region (BHCR). Companies like BioFactura, which is developing a smallpox therapeutic, and Emergent BioSolutions, which is advancing an anthrax vaccine, are two regional organizations BioBuzz has covered extensively.
